Genentech’s Hemlibra (emicizumab-kxwh) showed no new safety signals and continued to deliver consistent bleeding control in the final analysis of a long-term, late-stage hemophilia A study.
Germany’s BioNTech is acquiring Kite’s solid tumor neoantigen T-cell receptor (TCR) research-and-development platform and the Gilead company’s clinical manufacturing plant in Gaithersburg, Maryland.
Bristol Myers Squibb shared new details on the global biopharmaceutical firm’s Phase III research on a potential first-line treatment for people who have been diagnosed with recurrent or metastatic squamous cell carcinoma of the head and neck.
Regeneron continues to expand the company’s presence in New York. During the next six years, Regeneron will invest $1.8 billion to expand the company’s Tarrytown facilities. The investment will support the addition of 1,000 new jobs.
Boston-based Alexion Pharmaceuticals announced positive topline data from the company’s Phase III trial of Ultomiris (ravulizumab-cwvz) in adults with generalized myasthenia gravis.
Gilead Sciences Inc. announced new results from the Phase 2/3 CAPELLA trial evaluating lenacapavir, the company’s investigational, long-acting HIV-1 capsid inhibitor, in heavily treatment-experienced people living with multi-drug resistant HIV.
Paris-based Ipsen inked a licensing deal with Sweden’s IRLAB for mesdopetam, a potential drug for Parkinson’s disease.
Shape Therapeutics generated $112 million from a recent Series B financing round the Seattle biotechnology firm co-led with Decheng Capital and Breton Capital.
Scientists from the University of California, San Francisco have developed a tool that would give paralyzed persons who are unable to speak the ability to communicate through text that appears on a screen.
In a roundup of scientific studies on the novel coronavirus, new findings shed light on why chronic lung diseases that block the airways increase patients’ risks for severe Covid-19 and researchers say the blood disorder anemia should probably be added to the list of risk factors for poorer Covid-19 outcomes.
